22 May 2013
Keywords: UCB, ConfometRX, Research agreemnt, Neuroscience
Article | 24 February 2013
Belgium’s largest drugmaker UCB (Euronext Brussels: UCB) has signed a research agreement with California, USA-based ConfometRX to enable ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 February 2013
21 May 2013
© 2013 thepharmaletter.com